Philippines Drug Market More Than Doubles In 10 Years
This article was originally published in PharmAsia News
Executive SummaryThe Philippines' pharmaceuticals market probably has more than doubled in the past 10 years, from one worth about $976 million in 1999 to about $2.1 billion today. One of the reasons is the country remains one of the world's largest per capita buyers of medicines, equaling half of its health spending. Fewer than one-third of sales in the Philippines are generated by local drug makers, leading to drug prices two to 30 times higher for branded drugs than in surrounding Asian countries or in Canada. Generics account for 4 percent of total sales. (Click here for more
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.